Cancer News and Research

Latest Cancer News and Research

OriGene Technologies, ISB to create proteotypic PeptideAtlas and SRM/MRM mass spectrometry standard database

OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.

12 May 2010

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma.

12 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

Tensions escalate between Obama administration, health insurers

CQ HealthBeat: "WellPoint CEO Angela Braly is protesting comments President Obama made about how a health insurance company treated women diagnosed with breast cancer. [Her] letter marks another battle in the ongoing clash between the administration and the insurance companies — most prominently WellPoint — that hasn't lessened after enactment of the new health care law" (Norman, 5/10).

12 May 2010

Oncos Therapeutics completes € 4 million investment from HealthCap

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

12 May 2010

NY public hospital system plans to lay off about 500 workers and other state news

The Wall Street Journal: "New York City's Health & Hospitals Corp., the nation's largest public hospital system, plans to stanch a $1.2 billion budget gap in the next year's budget by laying off about 500 workers and ending contracts with 'a significant number' of physicians, its president said.

12 May 2010

Colorectal cancer screening rates much lower among African Americans: Study

Among African Americans, colorectal cancer is the third most common cause of cancer-related death. With the proper screening, it has a 90 percent cure rate, yet screening rates are much lower among this group than other ethnic groups.

12 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

Study confirms Resveratrol's impact on cognitive processes of the brain

The subject of extensive studies across the world, Resveratrol is proving to be a major talking point in the scientific community. And as evidence comes to light of the continuing beneficial effects of this compound, a further study by the University of Northumbria in the UK has confirmed what many scientists already believe to be the case - that Resveratrol could have a significant impact on the cognitive processes of the human brain.

12 May 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.

12 May 2010

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

If you have asthma or eczema, your hyper reactive immune system may lower your risk of some of the most common types of cancer, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

12 May 2010

FDA approves delivery of Cefepime in B. Braun's DUPLEX System

The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.

From B. Braun Melsungen AG 12 May 2010

Many pregnant women in the U.S. have insufficient vitamin D levels: Study

Seven out of every ten pregnant women in the United States are not getting enough Vitamin D according to a study published in the May issue of the American Journal of Obstetrics and Gynecology. While prenatal vitamins do raise Vitamin D levels during pregnancy, the study shows that higher doses may be needed for many women.

12 May 2010

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

IMBiotechnologies Ltd., a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration to market its lead product, Occlusin 500 Artificial Embolization Device in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours.

12 May 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab's revenues were DKK 107 million (USD 19 million) for the first quarter of 2010. In the same period of 2009, Genmab recognized revenues of DKK 250 million (USD 45 million).

12 May 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.

12 May 2010

Exelixis first-quarter revenues increase to $42.2 million

Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2010.

12 May 2010

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.

12 May 2010

Bionovo reports net loss of $4.7M for first-quarter 2010

Bionovo, Inc. today announced first quarter highlights and financial results for the three months ended March 31, 2010.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Cancer News and Research

Latest Cancer News and Research

OriGene Technologies, ISB to create proteotypic PeptideAtlas and SRM/MRM mass spectrometry standard database

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

Tensions escalate between Obama administration, health insurers

Oncos Therapeutics completes € 4 million investment from HealthCap

NY public hospital system plans to lay off about 500 workers and other state news

Colorectal cancer screening rates much lower among African Americans: Study

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

Study confirms Resveratrol's impact on cognitive processes of the brain

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

FDA approves delivery of Cefepime in B. Braun's DUPLEX System

Many pregnant women in the U.S. have insufficient vitamin D levels: Study

IMBio receives regulatory concurrence from FDA to market OCL 500 microspheres in the U.S.

Genmab reports revenues of DKK 107M for first-quarter 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

Exelixis first-quarter revenues increase to $42.2 million

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Bionovo reports net loss of $4.7M for first-quarter 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Understanding the DNA Damage Response in Innate Immunity eBook

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Newsletters you may be interested in